Logo image of MGX

METAGENOMI INC (MGX) Stock Fundamental Analysis

NASDAQ:MGX - Nasdaq - US59102M1045 - Common Stock - Currency: USD

1.48  +0.02 (+1.37%)

After market: 1.55 +0.07 (+4.73%)

Fundamental Rating

3

Taking everything into account, MGX scores 3 out of 10 in our fundamental rating. MGX was compared to 557 industry peers in the Biotechnology industry. While MGX has a great health rating, there are worries on its profitability. MGX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MGX had negative earnings in the past year.
In the past year MGX has reported a negative cash flow from operations.
MGX Yearly Net Income VS EBIT VS OCF VS FCFMGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

The Return On Assets of MGX (-26.17%) is better than 71.81% of its industry peers.
The Return On Equity of MGX (-36.65%) is better than 73.25% of its industry peers.
Industry RankSector Rank
ROA -26.17%
ROE -36.65%
ROIC N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGX Yearly ROA, ROE, ROICMGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -10 -20 -30 -40

1.3 Margins

MGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGX Yearly Profit, Operating, Gross MarginsMGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGX has been reduced compared to 1 year ago.
MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MGX Yearly Shares OutstandingMGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M
MGX Yearly Total Debt VS Total AssetsMGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

MGX has an Altman-Z score of -0.82. This is a bad value and indicates that MGX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MGX (-0.82) is better than 60.32% of its industry peers.
MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC9.03%
MGX Yearly LT Debt VS Equity VS FCFMGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MGX has a Current Ratio of 5.85. This indicates that MGX is financially healthy and has no problem in meeting its short term obligations.
MGX has a Current ratio of 5.85. This is comparable to the rest of the industry: MGX outperforms 59.78% of its industry peers.
MGX has a Quick Ratio of 5.85. This indicates that MGX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.85, MGX is in the better half of the industry, outperforming 60.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.85
Quick Ratio 5.85
MGX Yearly Current Assets VS Current LiabilitesMGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.95% over the past year.
The Revenue for MGX has decreased by -19.05% in the past year. This is quite bad
MGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 499.26% yearly.
EPS 1Y (TTM)29.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
Revenue 1Y (TTM)-19.05%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-63.02%

3.2 Future

Based on estimates for the next years, MGX will show a decrease in Earnings Per Share. The EPS will decrease by -6.12% on average per year.
Based on estimates for the next years, MGX will show a very negative growth in Revenue. The Revenue will decrease by -42.21% on average per year.
EPS Next Y11.84%
EPS Next 2Y12.71%
EPS Next 3Y-6.12%
EPS Next 5YN/A
Revenue Next Year-35.06%
Revenue Next 2Y-14.81%
Revenue Next 3Y-42.21%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
MGX Yearly Revenue VS EstimatesMGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M 40M 50M
MGX Yearly EPS VS EstimatesMGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MGX. In the last year negative earnings were reported.
Also next year MGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGX Price Earnings VS Forward Price EarningsMGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGX Per share dataMGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

MGX's earnings are expected to decrease with -6.12% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y12.71%
EPS Next 3Y-6.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

METAGENOMI INC

NASDAQ:MGX (6/18/2025, 8:08:24 PM)

After market: 1.55 +0.07 (+4.73%)

1.48

+0.02 (+1.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners26.46%
Inst Owner Change-11.73%
Ins Owners8.64%
Ins Owner Change0.66%
Market Cap55.32M
Analysts80
Price Target10.97 (641.22%)
Short Float %7.95%
Short Ratio5.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.17%
Min EPS beat(2)-16.48%
Max EPS beat(2)16.83%
EPS beat(4)3
Avg EPS beat(4)22.82%
Min EPS beat(4)-16.48%
Max EPS beat(4)56.01%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-19.73%
Min Revenue beat(2)-48.67%
Max Revenue beat(2)9.2%
Revenue beat(4)3
Avg Revenue beat(4)17.56%
Min Revenue beat(4)-48.67%
Max Revenue beat(4)67.99%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-22.1%
PT rev (3m)-41.58%
EPS NQ rev (1m)-10.75%
EPS NQ rev (3m)13.64%
EPS NY rev (1m)0%
EPS NY rev (3m)14.1%
Revenue NQ rev (1m)-4.33%
Revenue NQ rev (3m)30.4%
Revenue NY rev (1m)-3.05%
Revenue NY rev (3m)-1.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF N/A
P/OCF N/A
P/B 0.26
P/tB 0.26
EV/EBITDA N/A
EPS(TTM)-2.11
EYN/A
EPS(NY)-1.91
Fwd EYN/A
FCF(TTM)-2.8
FCFYN/A
OCF(TTM)-2.73
OCFYN/A
SpS1.21
BVpS5.69
TBVpS5.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.17%
ROE -36.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.76%
ROA(5y)N/A
ROE(3y)-27%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 45.28%
Cap/Sales 5.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.85
Quick Ratio 5.85
Altman-Z -0.82
F-Score3
WACC9.03%
ROIC/WACCN/A
Cap/Depr(3y)365.8%
Cap/Depr(5y)N/A
Cap/Sales(3y)36.38%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)29.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.86%
EPS Next Y11.84%
EPS Next 2Y12.71%
EPS Next 3Y-6.12%
EPS Next 5YN/A
Revenue 1Y (TTM)-19.05%
Revenue growth 3Y499.26%
Revenue growth 5YN/A
Sales Q2Q%-63.02%
Revenue Next Year-35.06%
Revenue Next 2Y-14.81%
Revenue Next 3Y-42.21%
Revenue Next 5YN/A
EBIT growth 1Y18.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.41%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-10.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.32%
OCF growth 3YN/A
OCF growth 5YN/A